Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × bisantrene × Clear all

Phase

Status

Sponsor Class

OTHER_GOV 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 43 Capecitabine 40 Radiotherapy 31 Gemcitabine 31 Paclitaxel 30 Oxaliplatin 30 Drug Therapy 29 Cyclophosphamide 29 Carboplatin 28 apatinib 27 tislelizumab 25 Irinotecan 25 Docetaxel 25 Fluorouracil 24 Bevacizumab 23 Surgical Procedures, Operative 19 Nivolumab 18 pembrolizumab 17 fludarabine 16 Metformin 16 Radiation 15 Exercise 15 camrelizumab 14 Blood Specimen Collection 14 S 1 (combination) 13 Control Groups 12 Neoadjuvant Therapy 11 Trastuzumab 10 Standard of Care 10 Pemetrexed 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04989335 2023-11-28

Bisantrene Combination for Resistant AML

Sheba Medical Center

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡